Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | F7 | P08709 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18137208 | 0.89 | MMP9 (0.59) | MMP9HCRTR1TDP1F7F2 | |
| SCHEMBL7931673 | 0.84 | MMP9 (0.64) | MMP9HCRTR1TDP1F7F2 | |
| SCHEMBL1143366 | 0.84 | MMP9 (0.64) | MMP9HCRTR1TDP1F7F2 | |
| SCHEMBL3523094 | 0.84 | MMP9 (0.64) | MMP9HCRTR1TDP1F7F2 | |
| SCHEMBL18068729 | 0.84 | MMP9 (0.64) | MMP9HCRTR1TDP1F7F2 | |
| SCHEMBL4037714 | 0.82 | ALDH1A1 (0.64) | MMP9HCRTR1TDP1F7F2 | |
| SCHEMBL4857933 | 0.82 | ALDH1A1 (0.64) | MMP9HCRTR1TDP1F7F2 | |
| SCHEMBL9686076 | 0.82 | MMP9 (0.75) | MMP9HCRTR1TDP1F7F2 | |
| SCHEMBL12354758 | 0.81 | MMP9 (0.61) | MMP9HCRTR1TDP1F7F2 | |
| SCHEMBL9002961 | 0.81 | ALDH1A1 (0.68) | MMP9HCRTR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | claimed |
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | MMP9 856/4885HDAC1 563/4885HDAC8 3399/4885 |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | MMP9 1037/4885HDAC1 622/4885HDAC8 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.